Associate Editor, OncLive
Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com
Heightened Histological Focus Fosters Treatment Advances in Non-clear Cell RCC
June 1st 2022Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.
Read More
Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment
June 1st 2022Emerging data with novel antibody-drug conjugates such as trastuzumab deruxtecan-nxki, vic-trastuzumab duocarmazine, and disitamab vedotin are showing encouraging activity in HER2-low breast cancer.
Read More
Novel Second-line Treatments Expand Therapeutic Options in Gastrointestinal Cancers
June 1st 2022Kelsey Klute, MD, discusses the importance of frontline checkpoint inhibitors in advanced gastric cancer, the need for predictive biomarkers in hepatocellular carcinoma, and research investigating immunotherapy in HER2-negative gastric and esophagus cancer and esophagus and gastroesophageal junction cancer.
Read More
Fighting Sexual Harassment Within Oncology Begins With Authentic, Actionable Conversations
May 31st 2022Ishwaria M. Subbiah, MD, MS, brings attention to the perpetrators of sexual harassment, outlines the nuances of how these experiences affect personal wellbeing and job satisfaction, and highlights the need for accountability as a first step toward systemic change across the oncology community.
Read More
Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma
May 27th 2022Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.
Read More
CDK4/6 Inhibition and Surgery Endeavors Help Break Ground for Innovative Breast Cancer Treatments
May 18th 2022Adam M. Brufsky, MD, PhD, emphasizes the importance of tyrosine kinase inhibitors in HER2-postive breast cancer and highlights the potential benefits of local salvage radiation therapy in patients with oligometastatic or de novo stage IV breast cancer.
Read More
A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC
May 18th 2022Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.
Read More
Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC
May 17th 2022Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.
Read More
Sexual Harassment Rates Across Oncology Call for Improved Policies and Protections
May 12th 2022Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.
Read More
Ibrutinib-Based Combination Therapy Displays Superior Efficacy Vs Monotherapy in MCL
May 9th 2022Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.
Read More
FDA-Approved CAR T-Cell Therapies Illuminate Advances in Multiple Myeloma
May 9th 2022Noopur S. Raje, MD, discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility.
Read More
COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL
May 6th 2022The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.
Read More
Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL
May 5th 2022The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.
Read More
The Future of Frontline CLL Treatment Hinges on Chemotherapy-Free Approaches
May 3rd 2022Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.
Read More
Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
April 26th 2022Oncolytic immunotherapy with talimogene laherparepvec and vusolimogene oderparepvec has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration.
Read More
Systemic Advances Shine, But Multidisciplinary Approaches Remain at Core of Skin Cancer Treatment
April 19th 2022Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.
Read More
Frontline Therapy Advances Are Current Focus in SCLC and NSCLC
April 18th 2022Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.
Read More
Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives
April 14th 2022New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.
Read More